drugset / Trial / NCT06517888
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Timeline
- Start
- 2025-01-17
- Primary completion
- 2029-08
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AAVAnc80-antiVEGF | Gene therapy (AAV / viral vector) | — | Other |